Evidence map›Paper›PMID 27478688›Full record

ArticleChemotherapy2016

Targeting Human

Mingjun Zhang, Jin He, Jing Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mingjun ZhangDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, USA.
Jin HeDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jing YangDepartment of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Cancer Research Institution, Guangzhou Medical University, Guangzhou, China.

Funding

Role of integrin VLA-6 in suppression of bone formation in myelomaR01CA193362 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2016 to 2020
$1.8M
Targeting adipocyte-secreted chemerin for chemotherapy resistance in myelomaR01CA190863 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YANG, JING · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA190863NCI NIH HHS R01 CA193362
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntibodiesImmunotherapyMonoclonalMultiple myelomaNeoplasm

Identifiers

PMID27478688
PMCPMC4966657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.